New Hope for Early Detection of Alzheimer's Disease
Advancements in the early detection of Alzheimer's disease, a common cause of dementia, promise a proactive era in healthcare, yet ensuring equitable access to these breakthroughs is critical. New technologies, ranging from immuno-infrared sensors to tau Positron Emission Tomography (PET) scans, can revolutionize Alzheimer's diagnosis by allowing treatment before symptoms start. The potential benefits are wide-reaching; for example, timely initiation of care could significantly impact disease progression. As a result, facilitating access to these benefits through the affordable implementation and equitable distribution of involved technologies is as important as ever. These are some of the barriers to early Alzheimer’s detection, according to a recent literature review published in the journal Cureus.
Many of these technologies are restricted to research settings and are not ready for clinical use. First, further study is needed to confirm their accuracy in diagnosing Alzheimer's. Second, even if patients are diagnosed accurately, costs may limit access to appropriate detection of the disease. Without insurance, PET scans, a common imaging procedure used to detect various conditions, including Alzheimer’s, can run from $1,300 to more than $4,600, putting them out of reach for many. It follows that individuals are unlikely to seek screenings if prices are high even when they may be needed.
Many of these technologies are restricted to research settings and are not ready for clinical use. First, further study is needed to confirm their accuracy in diagnosing Alzheimer's. Second, even if patients are diagnosed accurately, costs may limit access to appropriate detection of the disease. Without insurance, PET scans, a common imaging procedure used to detect various conditions, including Alzheimer’s, can run from $1,300 to more than $4,600, putting them out of reach for many. It follows that individuals are unlikely to seek screenings if prices are high even when they may be needed.
Image Source: michelle henderson
In regards to blood tests, companies need approval from the Food and Drug Administration (FDA) before they are commercially marketed. Prices have not been set, but they are likely to be high as health insurance coverage may not be able to offset costs. This can be seen in the example of a new blood test marketed for Alzheimer’s detection. Costs are not the only obstacle. Racial and geographic disparities already exist in dementia care, which could worsen if new technologies become unaffordable for disadvantaged groups. For example, African Americans are about twice as likely to develop Alzheimer's and related dementias compared to Caucasians, yet Black participants in Alzheimer's research studies were 35% less likely to be diagnosed than whites, according to the National Institutes for Health. This suggests racial gaps in diagnosis that could be increased if innovative but expensive diagnostic technologies are inaccessible to underserved minority communities.
Early detection shows promise for preserving health and families’ well-being. However, for these benefits to be fully realized, tests must be made affordable, accessible, and appropriately implemented on a broader scale. More work to standardize equipment and tests and integrate multiple diagnosis approaches is needed to translate intriguing research into equitable clinical solutions. Widespread screening will require defining appropriate ages and frequencies.
With Alzheimer's cases projected to nearly quadruple in the next 50 years, by which time approximately 1 in 45 Americans will be afflicted with the disease, it is urgent we find ways to enable earlier detection for all who could benefit. If done properly, new technologies could grant many at-risk populations more time to receive treatment. Earlier detection is welcome progress, but must reach the populations who need it most.
Early detection shows promise for preserving health and families’ well-being. However, for these benefits to be fully realized, tests must be made affordable, accessible, and appropriately implemented on a broader scale. More work to standardize equipment and tests and integrate multiple diagnosis approaches is needed to translate intriguing research into equitable clinical solutions. Widespread screening will require defining appropriate ages and frequencies.
With Alzheimer's cases projected to nearly quadruple in the next 50 years, by which time approximately 1 in 45 Americans will be afflicted with the disease, it is urgent we find ways to enable earlier detection for all who could benefit. If done properly, new technologies could grant many at-risk populations more time to receive treatment. Earlier detection is welcome progress, but must reach the populations who need it most.
Featured Image Source: National Cancer Institute
RELATED ARTICLES
Vertical Divider
|
Vertical Divider
|
Vertical Divider
|